ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 142 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $34,123 | -84.1% | 8,343 | -38.8% | 0.01% | -81.5% |
| Q1 2024 | $214,872 | +73.2% | 13,634 | +66.5% | 0.03% | +12.5% |
| Q4 2023 | $124,048 | +241.8% | 8,188 | +352.6% | 0.02% | +118.2% |
| Q3 2023 | $36,289 | +65.1% | 1,809 | +132.2% | 0.01% | +57.1% |
| Q2 2023 | $21,976 | +65.3% | 779 | +0.8% | 0.01% | +75.0% |
| Q1 2023 | $13,296 | +14.0% | 773 | +33.5% | 0.00% | -20.0% |
| Q4 2022 | $11,661 | -2.8% | 579 | +8.4% | 0.01% | 0.0% |
| Q3 2022 | $12,000 | – | 534 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 187,143 | $765,415 | 25.27% |
| Decheng Capital LLC | 3,070,442 | $12,558,107 | 3.85% |
| MPM BioImpact LLC | 1,450,000 | $5,930,500 | 0.92% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $3,932,478 | 0.80% |
| Eventide Asset Management | 8,547,896 | $34,960,895 | 0.60% |
| 5AM Venture Management, LLC | 490,000 | $2,004,100 | 0.45% |
| Matrix Capital Management Company, LP | 13,959,973 | $57,096,290 | 0.44% |
| Values First Advisors, Inc. | 74,925 | $306,443 | 0.18% |
| Boxer Capital, LLC | 450,000 | $1,840,500 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 255,201 | $1,044 | 0.07% |